Filing Flows › UroGen Pharma (URGN) › Stock forecast & fair value
UroGen Pharma (URGN) stock forecast and price target
UroGen Pharma (URGN) trades at $24.75. 7 analysts' median price target is $60.00 (+142%), from $56.00 to $75.00.
UroGen Pharma's latest quarter
UroGen Pharma, Q3 2026: revenue $89.0M (+224% year over year), operating margin 9.4%, net loss $1.5M, operating cash flow −$15.2M. The chart follows the revenue to costs, profit and cash.
Questions
What is the price target for URGN stock?
The median of 7 analysts' 12-month targets is $60.00, +142% from $24.75; the range is $56.00 to $75.00. The average rating is strong buy.
Does UroGen Pharma usually beat earnings estimates?
It beat the consensus EPS estimate in 20% of the quarters on record.
Is URGN stock a buy?
Filing Flows does not give advice. It shows what analysts expect, what each valuation method implies and the figures behind them, read from SEC filings, so you can judge for yourself.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.